Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-04-08 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 150.2KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references an Appendix 2A and details share issuance dates and quantities. The content is a regulatory compliance notice about share issuance without disclosure under part 6D.2 of the Corporations Act. The document length is short (1454 characters) and it does not contain financial statements or detailed financial data. It is not an annual report, earnings release, or capital update but a formal regulatory announcement about share issuance compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-08 English
Telix General Meeting Chairman and CEO Addresses 7 pages 219.9KB
AGM Information Classification · 95% confidence The document is an ASX release containing the Chairman and CEO addresses at a General Meeting of Telix Pharmaceuticals Limited. It discusses shareholder approval sought to refresh the company's 15% placement capacity under ASX Listing Rule 7.1, details of recent mergers and acquisitions (M&A) strategy, and strategic acquisitions. The content is focused on the business strategy, corporate development, and M&A activities rather than financial results or detailed financial statements. The document is a communication made at a General Meeting, not a full Annual Report, Interim Report, or Earnings Release. It is not a Proxy Solicitation or Voting Results announcement, but rather the Chairman and CEO addresses at the General Meeting. Therefore, the document fits best under AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or General Meeting.
2024-04-04 English
Telix General Meeting Presentation 16 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation containing forward-looking statements, company strategy, product pipeline updates, manufacturing and supply chain information, and M&A strategy. It includes a chairman's address, CEO's address, and formal business items typical of a shareholder meeting presentation. The content is focused on investor information, company vision, and strategic updates rather than financial statements or regulatory filings. The presence of slides, images, and structured agenda points further supports that this is an investor presentation. There is no indication that this is an annual report, earnings release, or regulatory filing. The document length and detail also exclude it from being a brief announcement or a certification. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-04-04 English
Telix General Meeting Results 3 pages 205.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX release titled 'Telix Results of General Meeting' dated 5 April 2024. It reports the outcomes of resolutions voted on at a General Meeting, including detailed voting statistics for each resolution. The text references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which relate to disclosure of voting results. The document does not contain financial statements or management discussion but focuses solely on the official results of shareholder votes at the meeting. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length (8701 characters) and content confirm it is the actual voting results report, not just an announcement of a report or a proxy solicitation.
2024-04-04 English
Notification regarding unquoted securities - TLX 6 pages 20.1KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities under an employee incentive scheme by Telix Pharmaceuticals Limited. It details the number and type of securities issued, dates, and mentions key management personnel involved. The document is structured as an official announcement to the ASX about securities issuance, including references to relevant listing rules and exceptions. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. This fits the category of a Share Issue/Capital Change announcement, as it informs about new securities issued and changes in capital structure.
2024-03-26 English
Application for quotation of securities - TLX 6 pages 18.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue dates, and the class of securities. This type of filing is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital change. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about securities quotation.
2024-03-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.